MIR100HG is expressed at high levels in triple-negative breast cancer (Chen et al., 2020b), laryngeal squamous cell carcinoma (Huang et al., 2019), gastric cancer (Li et al., 2019b) and colorectal cancer (Li et al., 2019a). Here, MIR100HG is linked to triple-negative breast carcinoma.